-
Something wrong with this record ?
Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies
B. Kovandova, A. Slavcev, Z. Sekerkova, E. Honsova, P. Trunecka,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV16-27477A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Medline Complete (EBSCOhost)
from 2016-01-01 to 1 year ago
PubMed
30054978
DOI
10.1111/tan.13354
Knihovny.cz E-resources
- MeSH
- Tissue Donors MeSH
- Child MeSH
- Adult MeSH
- Transplantation, Homologous MeSH
- Isoantibodies blood MeSH
- Complement C1q metabolism MeSH
- Complement C3d metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Follow-Up Studies MeSH
- Graft Survival * MeSH
- Prognosis MeSH
- Graft Rejection blood diagnosis immunology pathology MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Histocompatibility Testing methods MeSH
- Liver Transplantation * MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The aim of our study was to evaluate the relevance of complement-binding donor-specific antibodies (DSA) for prediction of antibody-mediated rejection (AMR) after liver transplantation. Sera from 123 liver transplant recipients were retrospectively defined for HLA specificity and complement-fixing activity using the single antigen beads, C1q and C3d techniques. Liver-recipients' sera were tested before transplantation, 3, 6 months and 1 year after transplantation. Patients were followed up for graft survival and rejection incidence for 1 year after transplantation. All patients with pretransplant complement-binding DSA developed severe AMR after transplantation, while three recipients out of four, who produced de novo complement-fixing DSA, developed AMR. Definition of DSA with respect to complement-fixing activity may provide clinically relevant information about the risk of AMR after liver transplantation.
Clinic of Hepatology IKEM Prague Czech Republic
Department of Clinical and Transplantation Pathology IKEM Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035108
- 003
- CZ-PrNML
- 005
- 20191014101237.0
- 007
- ta
- 008
- 191007s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/tan.13354 $2 doi
- 035 __
- $a (PubMed)30054978
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kovandova, Barbora $u Department of Immunogenetics, IKEM, Prague, Czech Republic.
- 245 10
- $a Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies / $c B. Kovandova, A. Slavcev, Z. Sekerkova, E. Honsova, P. Trunecka,
- 520 9_
- $a The aim of our study was to evaluate the relevance of complement-binding donor-specific antibodies (DSA) for prediction of antibody-mediated rejection (AMR) after liver transplantation. Sera from 123 liver transplant recipients were retrospectively defined for HLA specificity and complement-fixing activity using the single antigen beads, C1q and C3d techniques. Liver-recipients' sera were tested before transplantation, 3, 6 months and 1 year after transplantation. Patients were followed up for graft survival and rejection incidence for 1 year after transplantation. All patients with pretransplant complement-binding DSA developed severe AMR after transplantation, while three recipients out of four, who produced de novo complement-fixing DSA, developed AMR. Definition of DSA with respect to complement-fixing activity may provide clinically relevant information about the risk of AMR after liver transplantation.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a komplement C1q $x metabolismus $7 D015922
- 650 _2
- $a komplement C3d $x metabolismus $7 D015933
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a rejekce štěpu $x krev $x diagnóza $x imunologie $x patologie $7 D006084
- 650 12
- $a přežívání štěpu $7 D006085
- 650 _2
- $a testování histokompatibility $x metody $7 D006650
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a isoprotilátky $x krev $7 D007518
- 650 12
- $a transplantace jater $7 D016031
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a dárci tkání $7 D014019
- 650 _2
- $a homologní transplantace $7 D014184
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Slavcev, Antonij $u Department of Immunogenetics, IKEM, Prague, Czech Republic.
- 700 1_
- $a Sekerkova, Zuzana $u Department of Immunogenetics, IKEM, Prague, Czech Republic.
- 700 1_
- $a Honsova, Eva $u Department of Clinical & Transplantation Pathology, IKEM, Prague, Czech Republic.
- 700 1_
- $a Trunecka, Pavel $u Clinic of Hepatology, IKEM, Prague, Czech Republic.
- 773 0_
- $w MED00195031 $t HLA $x 2059-2310 $g Roč. 92 Suppl 2, č. - (2018), s. 34-37
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30054978 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014101701 $b ABA008
- 999 __
- $a ok $b bmc $g 1451768 $s 1073658
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 92 Suppl 2 $c - $d 34-37 $e - $i 2059-2310 $m HLA $n HLA $x MED00195031
- GRA __
- $a NV16-27477A $p MZ0
- LZP __
- $a Pubmed-20191007